1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
MicroPort CardioFlow Medtech Corporation

MicroPort CardioFlow Medtech Corporation

0.14
EUR
- -
- -
Mar 30Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.01
0.03
0.07
0.08
0.1
0.11
0.58
- -
Basic EPS, GAAP
-0.02
-0.04
-0.13
-0.06
-0.14
-0.14
-0.01
-0.19
- -
Free Cash Flow per Basic Share
-0.04
-0.06
-0.05
-0.09
-0.07
-0.07
-0.08
-0.39
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.08
0.04
-0.11
1.01
0.83
0.7
0.64
0.2
0.2
Tangible Book Value per Share
0.02
-0.03
-0.19
0.93
0.78
0.65
0.58
0.09
0.09
Basic Weighted Avg Shares
473
473
473
466
473
473
468
98
869
Sales/Revenue/Turnover
- -
3
16
32
36
47
51
57
- -
Operating Margin (%)
- -
-574.13
-178.36
-101.19
-132.21
-104.59
-44.16
-35.88
- -
Depreciation Expense
- -
2
4
7
11
10
12
14
- -
Net Income, GAAP
-9
-21
-61
-29
-66
-67
-7
-19
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-672.13
-383.02
-91.26
-181.02
-140.25
-13.68
-32.99
- -
Working Capital
-6
-29
-109
382
304
261
173
225
225
LT Debt
2
2
1
14
9
6
2
209
209
Total Equity
40
19
-53
486
399
330
309
256
256
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-70.51
- -
- -
-14.89
-18.26
-2.19
-6.72
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
9
11
23
LT Borrowings
1
27
188
LT Finance Leases
1
1
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
475
482
1,273
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
233
238
373
Cash, Cash Equivalents & STI
189
184
179
Accounts Receivable, Net
19
31
69
Inventories
19
15
87
Total Current Liabilities
60
34
148
Payables & Accruals
- -
- -
- -
ST Debt
9
11
23
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-215.61%
-17.09%
Free Cash Flow
- -
11.55%
2.18%
Net Income, GAAP
- -
31.71%
170.85%
Sales/Revenue/Turnover
- -
32.66%
12.28%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
47
2024
- -
- -
51
2025
- -
- -
57

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.14
2024
- -
- -
-0.01
2025
- -
- -
-0.19

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Guo Ming Chen
Full Time Employees
421
Sector
Health technology
Industry
Medical specialties
Address
No. 501 Niudun Road Shanghai SH China 201203
IPO Date
Feb 4, 2021
Website
cardioflowmedtech.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
MicroPort CardioFlow Medtech Corporation (2160.HK), headquartered in Shanghai, China and founded in 2009, develops, manufactures and commercializes transcatheter and surgical medical devices focused on structural heart diseases including valvular heart conditions and left atrial appendage closure; its core products comprise the VitaFlow series transcatheter aortic valve implantation (TAVI) systems such as VitaFlow Liberty (the world's first electric retrievable TAVI system with EU CE-MDR certification in 2024), VitaFlow Liberty Flex and VitaFlow IV, Alwide balloon catheters including Alwide Plus, procedural accessories like Alpass Introducer Set and Angelguide super stiff guidewire, AnchorMan left atrial appendage closure (LAAC) systems, transcatheter mitral valve (TMV) and tricuspid valve (TTV) products in development, and surgical valves and accessories. The company serves physicians and patients through total solutions for structural heart treatments, with its TAVI products and accessories implanted in over 700 core hospitals across more than 20 countries and regions worldwide, treating over 10,000 patients; it operates primarily in China and internationally. Recent developments include the first commercial implantations of VitaFlow Liberty in Türkiye in 2025 highlighting its retrievability and efficiency, a strategic investment as largest shareholder in partner 4C Medical's US$175 million Series D financing in March 2025 to advance transcatheter mitral valve replacement, and a proposed US$680 million merger with MicroPort Cardiac Rhythm Management (a MicroPort Scientific subsidiary) announced in September 2025 to create a diversified global heart disease platform under Hong Kong Listing Rules Chapter 18A.